查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1845905

全球茲卡疫苗市場規模（按疫苗類型、應用、區域範圍和預測）

Global Zika Vaccines Market Size By Vaccine Type(Inactivated Vaccine, Purified Inactivated Vaccine, DNA Vaccine), By Application (Clinics, Academic and Research, Hospitals), By Geographic Scope And Forecast
出版日期: | 出版商: Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

茲卡疫苗市場規模及預測

預計茲卡疫苗市場在 2024 年的價值將達到 136.91 億美元，並在 2031 年達到 197.89 億美元，2024 年至 2031 年的複合年成長率為 5.4%。

茲卡病毒在各國的感染疾病不斷上升，推動了全球寨卡疫苗市場的發展。大型製藥公司正在加大對新疫苗研發的投入，從而推動全球市場的擴張。此外，不斷加強的推廣宣傳活動以及與世界衛生組織在疫苗研發方面的合作研究也推動了寨卡疫苗市場的成長。全球茲卡疫苗市場報告對市場進行了全面的評估，全面分析了關鍵細分市場、趨勢、市場促進因素、限制因素、競爭格局以及影響市場的關鍵因素。

茲卡疫苗的全球市場定義

茲卡病毒（ZIKV），又稱黃病毒，屬於黃病毒科，是一種蚊媒感染疾病，可透過蚊子、輸血、性接觸以及受感染的孕婦傳播給嬰兒。蚊子茲卡病毒，並將病毒傳播給叮咬者。茲卡病毒感染可導致胎兒神經系統異常和先天性畸形。目前，茲卡病毒疫苗正在研發中，用於預防和控制茲卡病毒引起的疾病。

目前用於預防茲卡病毒的疫苗種類繁多，包括mRNA疫苗、DNA疫苗和去活化疫苗。該病毒也可由受感染的孕婦傳播給胎兒。 PCR檢測可用於診斷感染。然而，只有四分之一的感染者會出現症狀。 2016年11月，世界衛生組織（WHO）宣布茲卡病毒不再構成公共衛生威脅。然而，由於大多數病例無症狀，該病毒仍然受到國際社會關注。

全球茲卡疫苗市場概覽

茲卡病毒活躍病例的不斷增加以及茲卡病毒對其影響日益成長的擔憂，是推動寨卡疫苗市場發展和全球茲卡病毒疫苗需求成長的主要因素。茲卡病毒的日益流行正刺激有效疫苗的生產。大眾對病毒認知的提高鼓勵了這些疫苗的使用，從而推動了市場的發展。疫苗研發投入的不斷增加以及政府政策的推出也推動了茲卡疫苗市場的成長。

此外，茲卡病毒需求的不斷成長以及疫苗技術的進步也有望促進業務成長和發展。然而，限制市場成長和發展的因素包括價格昂貴以及偏遠地區民眾對疫苗的認知度和認可度較低。低度開發國家對先進技術的使用缺乏了解也限制了市場的成長。此外，這些疫苗可能對人體產生一些有害影響，這反過來又可能抑制市場成長。

目錄

第1章 全球茲卡疫苗市場簡介

  • 市場定義
  • 市場區隔
  • 調查時間表
  • 先決條件
  • 限制

第2章：已驗證的市場調查方法

  • 資料探勘
  • 數據三角測量
  • 自下而上的方法
  • 自上而下的方法
  • 調查流程
  • 業界專家的重要見解
  • 資料來源

第3章執行摘要

  • 市場概況
  • 生態測繪
  • 絕對的商機
  • 市場吸引力
  • 全球寨卡疫苗市場區域分析
  • 全球茲卡疫苗市場（按疫苗類型分類）（百萬美元）
  • 全球寨卡疫苗市場應用情形（百萬美元）
  • 未來市場機遇
  • 世界市場結構
  • 產品生命線

第4章 全球茲卡疫苗市場展望

  • 全球茲卡疫苗的演變
  • 驅動程式
    • 促進要素1
    • 促進要素2
  • 阻礙因素
    • 阻礙因素1
    • 阻礙因素2
  • 機會
    • 機會 1
    • 機會 2
  • 波特五力模型
  • 價值鏈分析
  • 定價分析
  • 宏觀經濟分析

第5章全球茲卡疫苗市場（依疫苗類型）

  • 概述
  • 去活化疫苗
  • 純化去活化疫苗
  • DNA疫苗

第6章 全球茲卡疫苗市場（按應用）

  • 概述
  • 診所
  • 學術和研究機構
  • 醫院
  • 其他

第7章全球茲卡疫苗市場（按地區）

  • 概述
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲
  • 中東和非洲
    • 阿拉伯聯合大公國
    • 沙烏地阿拉伯
    • 南非
    • 其他中東和非洲地區

第8章全球茲卡疫苗市場競爭格局

  • 概述
  • 各公司市場排名
  • 主要進展
  • 公司地理分佈
  • 公司產業足跡
  • ACE矩陣

第9章：公司簡介

  • Inovio Pharmaceuticals Inc
  • Emergent BioSolutions Inc
  • Gilead Sciences Inc
  • Precigen Inc
  • LUMOS PHARMA
  • Hawaii Biotech Inc
  • Sanofi
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Bharat Biotech

第 10 章：經過驗證的市場情報

  • 關於已驗證的市場情報
  • 動態資料視覺化
簡介目錄
Product Code: 39420

Zika Vaccines Market Size And Forecast

Zika Vaccines Market size was valued at USD 13,691 Million in 2024 and is projected to reach USD 19,789 Million by 2031, growing at a CAGR of 5.4% from 2024 to 2031.

The increased prevalence of Zika virus disease in countries is driving the global Zika Vaccines Market forward. Major pharmaceutical companies that have increased the investment in R&D for the production of new vaccines is driving the global market's expansion. In addition, there has been an increase in outreach campaigns and a partnership study for vaccine development with the World Health Organization which is driving the growth of Zika Vaccines Market. The Global Zika Vaccines Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global Zika Vaccines Market Definition

Zika virus (ZIKV), also known as a flavivirus, that is from the Flaviviridae family, is a mosquito-borne disease that spreads to humans through mosquitos, blood transfusions, sex, and from an infected pregnant woman to her baby. After biting a zika-infected human, a mosquito becomes infected with the virus and spreads it to anyone they sting. Infection with the Zika virus may result in neurological abnormalities and congenital birth defects in the fetus. Zika vaccines are being designed to help people prevent and manage diseases caused by the Zika virus.

There are many varieties of vaccines used to protect against the Zika virus, including mRNA vaccines, DNA vaccines, and inactivated vaccines. In addition, the virus can be transmitted from an infected pregnant woman to her fetus. PCR is used for the diagnosis of the infection. However, only 1 out of every 4 people with the virus has the risk of developing symptoms. In November 2016, the World Health Organization (WHO) announced that the Zika virus is no longer a threat to public health, which has been an international concern since the major cases of the virus are asymptomatic.

Global Zika Vaccines Market Overview

The increasing prevalence of the active Zika virus as well as increased concern about the consequences of the Zika virus has increased the market for Zika vaccines and is the primary factor driving the global Zika virus vaccine demand. The rising prevalence of Zika fever is fueling the production of effective vaccines. The growing public understanding of the virus is encouraging the use of these vaccines which in turn is driving the market. Increased investment in vaccine research and development, as well as favorable government policies, are also the growth drivers for the Zika Vaccines Market.

In addition, the increase in demand for zika virus and advancements in vaccine technologies are expected to help in business growth and development. However, the factors restraining the market growth and development are a lack of affordability and a lack of recognition and awareness in remote areas. Also, the lack of knowledge in using advanced technology in underdeveloped countries is also restraining the market growth. In addition, these vaccines might cause some harmful effects on the body of individuals which in turn can restrain the market growth.

Global Zika Vaccines Market: Segmentation Analysis

The Global Zika Vaccines Market is segmented based on Vaccine Type, Application, and Geography.

Zika Vaccines Market, By Vaccine Type

Inactivated Vaccine

Purified Inactivated Vaccine

DNA Vaccine

Based on Vaccine Type, the market is bifurcated into Inactivated Vaccine, Purified Inactivated Vaccine, and DNA Vaccine. Inactivated Vaccine dominated the market in 2019 and is likely to continue in the forecast period. Purified Inactivated Vaccine has good market potentials in the forecast period owing to the evolution of modern medicines and equipment technologies.

Zika Vaccines Market, By Application

Clinics

Academic and Research

Hospitals

Others

Based on Application, the market is bifurcated into Clinics, Academic and Research, Hospitals, and Others. The hospital segment accounted for the strongest share in 2019, and this pattern is expected to continue. An increase in patients with Zika virus disease would necessitate hospitalization. Also, the early availability of new drugs in hospitals is expected to fuel the segment's development.

Zika Vaccines Market, By Geography

North America

Europe

Asia Pacific

Rest of the world

Based on regional analysis, the Global Zika Vaccines Market is classified into North America, Europe, Asia Pacific, and the Rest of the world. In 2019, the Rest of the world led the global Zika Vaccines Market, and this pattern is projected to continue over the years. The region's domination can be due to a rise in people infected with the Zika virus in countries such as Brazil, Bolivia, and Peru, as well as the involvement of major players.

Key Players

The "Global Zika Vaccines Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are Inovio Pharmaceuticals, Inc., Emergent BioSolutions Inc., Gilead Sciences Inc., Precigen, Inc., LUMOS PHARMA, Hawaii Biotech Inc., Sanofi, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, and Bharat Biotech.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

  • Ace Matrix Analysis
  • The Ace Matrix provided in the report would help to understand how the major key players involved in this industry are performing as we provide a ranking for these companies based on various factors such as service features & innovations, scalability, innovation of services, industry coverage, industry reach, and growth roadmap. Based on these factors, we rank the companies into four categories as Active, Cutting Edge, Emerging, and Innovators.
  • Market Attractiveness
  • The image of market attractiveness provided would further help to get information about the region that is majorly leading in the global Zika Vaccines market. We cover the major impacting factors that are responsible for driving the industry growth in the given region.
  • Porter's Five Forces
  • The image provided would further help to get information about Porter's five forces framework providing a blueprint for understanding the behavior of competitors and a player's strategic positioning in the respective industry. The porter's five forces model can be used to assess the competitive landscape in global Zika Vaccines market, gauge the attractiveness of a certain sector, and assess investment possibilities.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL ZIKA VACCINES MARKET

  • 1.1 Market Definition
  • 1.2 Market Segmentation
  • 1.3 Research Timelines
  • 1.4 Assumptions
  • 1.5 Limitations

2 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

  • 2.1 Data Mining
  • 2.2 Data Triangulation
  • 2.3 Bottom-Up Approach
  • 2.4 Top-Down Approach
  • 2.5 Research Flow
  • 2.6 Key Insights from Industry Experts
  • 2.7 Data Sources

3 EXECUTIVE SUMMARY

  • 3.1 Market Overview
  • 3.2 Ecology Mapping
  • 3.3 Absolute Market Opportunity
  • 3.4 Market Attractiveness
  • 3.5 Global Zika Vaccines Market Geographical Analysis (CAGR %)
  • 3.6 Global Zika Vaccines Market, By Vaccine Type (USD Million)
  • 3.7 Global Zika Vaccines Market, By Application (USD Million)
  • 3.8 Future Market Opportunities
  • 3.9 Global Market Split
  • 3.10 Product Life Line

4 GLOBAL ZIKA VACCINES MARKET OUTLOOK

  • 4.1 Global Zika Vaccines Evolution
  • 4.2 Drivers
    • 4.2.1 Driver 1
    • 4.2.2 Driver 2
  • 4.3 Restraints
    • 4.3.1 Restraint 1
    • 4.3.2 Restraint 2
  • 4.4 Opportunities
    • 4.4.1 Opportunity 1
    • 4.4.2 Opportunity 2
  • 4.5 Porters Five Force Model
  • 4.6 Value Chain Analysis
  • 4.7 Pricing Analysis
  • 4.8 Macroeconomic Analysis

5 GLOBAL ZIKA VACCINES MARKET, BY VACCINE TYPE

  • 5.1 Overview
  • 5.2 Inactivated Vaccine
  • 5.3 Purified Inactivated Vaccine
  • 5.4 DNA Vaccine

6 GLOBAL ZIKA VACCINES MARKET, BY APPLICATION

  • 6.1 Overview
  • 6.2 Clinics
  • 6.3 Academic and Research
  • 6.4 Hospitals
  • 6.5 Others

7 GLOBAL ZIKA VACCINES MARKET, BY GEOGRAPHY

  • 7.1 Overview
  • 7.2 North America
    • 7.2.1 U.S.
    • 7.2.2 Canada
    • 7.2.3 Mexico
  • 7.3 Europe
    • 7.3.1 Germany
    • 7.3.2 U.K.
    • 7.3.3 France
    • 7.3.4 Italy
    • 7.3.5 Spain
    • 7.3.6 Rest of Europe
  • 7.4 Asia Pacific
    • 7.4.1 China
    • 7.4.2 Japan
    • 7.4.3 India
    • 7.4.4 Rest of Asia Pacific
  • 7.5 Latin America
    • 7.5.1 Brazil
    • 7.5.2 Argentina
    • 7.5.3 Rest of Latin America
  • 7.6 Middle-East and Africa
    • 7.6.1 UAE
    • 7.6.2 Saudi Arabia
    • 7.6.3 South Africa
    • 7.6.4 Rest of Middle-East and Africa

8 GLOBAL ZIKA VACCINES MARKET COMPETITIVE LANDSCAPE

  • 8.1 Overview
  • 8.2 Company Market Ranking
  • 8.3 Key Developments
  • 8.4 Company Regional Footprint
  • 8.5 Company Industry Footprint
  • 8.6 ACE Matrix

9 COMPANY PROFILES

  • 9.1 Inovio Pharmaceuticals Inc
    • 9.1.1 Company Overview
    • 9.1.2 Company Insights
    • 9.1.3 Product Benchmarking
    • 9.1.4 Key Development
    • 9.1.5 Winning Imperatives
    • 9.1.6 Current Focus & Strategies
    • 9.1.7 Threat from Competition
    • 9.1.8 SWOT Analysis
  • 9.2 Emergent BioSolutions Inc
    • 9.2.1 Overview
    • 9.2.2 Financial Performance
    • 9.2.3 Product Outlook
    • 9.2.4 Key Developments
  • 9.3 Gilead Sciences Inc
    • 9.3.1 Overview
    • 9.3.2 Financial Performance
    • 9.3.3 Product Outlook
    • 9.3.4 Key Developments
  • 9.4 Precigen Inc
    • 9.4.1 Overview
    • 9.4.2 Financial Performance
    • 9.4.3 Product Outlook
    • 9.4.4 Key Developments
  • 9.5 LUMOS PHARMA
    • 9.5.1 Overview
    • 9.5.2 Financial Performance
    • 9.5.3 Product Outlook
    • 9.5.4 Key Developments
  • 9.6 Hawaii Biotech Inc
    • 9.6.1 Overview
    • 9.6.2 Financial Performance
    • 9.6.3 Product Outlook
    • 9.6.4 Key Developments
  • 9.7 Sanofi
    • 9.7.1 Overview
    • 9.7.2 Financial Performance
    • 9.7.3 Product Outlook
    • 9.7.4 Key Developments
  • 9.8 GlaxoSmithKline plc
    • 9.8.1 Overview
    • 9.8.2 Financial Performance
    • 9.8.3 Product Outlook
    • 9.8.4 Key Developments
  • 9.9 Takeda Pharmaceutical Company Limited
    • 9.9.1 Overview
    • 9.9.2 Financial Performance
    • 9.9.3 Product Outlook
    • 9.9.4 Key Developments
  • 9.10 Bharat Biotech
    • 9.10.1 Overview
    • 9.10.2 Financial Performance
    • 9.10.3 Product Outlook
    • 9.10.4 Key Developments

10 VERIFIED MARKET INTELLIGENCE

  • 10.1 About Verified Market Intelligence
  • 10.2 Dynamic Data Visualization